Lion Biotechnologies Inc (LBIO) : Venbio Select Advisor reduced its stake in Lion Biotechnologies Inc by 1.87% during the most recent quarter end. The investment management company now holds a total of 4,257,347 shares of Lion Biotechnologies Inc which is valued at $32,142,970 after selling 81,210 shares in Lion Biotechnologies Inc , the firm said in a disclosure report filed with the SEC on Nov 14, 2016.Lion Biotechnologies Inc makes up approximately 6.01% of Venbio Select Advisor’s portfolio.
Other Hedge Funds, Including , Group One Trading reduced its stake in LBIO by selling 1,042 shares or 5.9% in the most recent quarter. The Hedge Fund company now holds 16,630 shares of LBIO which is valued at $125,557. Lion Biotechnologies Inc makes up approx 0.01% of Group One Trading’s portfolio.Blackrock Group Ltd boosted its stake in LBIO in the latest quarter, The investment management firm added 675,700 additional shares and now holds a total of 688,872 shares of Lion Biotechnologies Inc which is valued at $4,236,563.Rhumbline Advisers reduced its stake in LBIO by selling 3,060 shares or 5.85% in the most recent quarter. The Hedge Fund company now holds 49,216 shares of LBIO which is valued at $302,678.New York State Common Retirement Fund boosted its stake in LBIO in the latest quarter, The investment management firm added 9,800 additional shares and now holds a total of 51,000 shares of Lion Biotechnologies Inc which is valued at $313,650. Td Asset Management Inc added LBIO to its portfolio by purchasing 14,931 company shares during the most recent quarter which is valued at $88,093.
Lion Biotechnologies Inc closed down -0.05 points or -0.67% at $7.45 with 1,75,956 shares getting traded on Monday. Post opening the session at $7.5, the shares hit an intraday low of $7.3373 and an intraday high of $7.55 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
Lion Biotechnologies Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing adoptive cell therapy (ACT) using autologous tumor infiltrating lymphocytes (TILs) for the treatment of metastatic melanoma and other solid cancers. The Company’s program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL) which are T cells derived from patients’ tumors for the treatment of metastatic melanoma. Once the TILs have been multiplied to a sufficient number ex vivo and after the patient has completed the non-myeloablative chemotherapeutic regimen the TILs are infused into the patient along with a high dose of interleukin2 (IL2) a protein that stimulates the immune system.